The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis
- 5 March 2021
- journal article
- research article
- Published by Elsevier BV in Journal of Cystic Fibrosis
- Vol. 20 (6), 932-936
- https://doi.org/10.1016/j.jcf.2021.02.012
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (P30 DK089507, R01HL103965, U01 HL114589, UL1 TR000423, UM1 HL119073)
- U.S. Food and Drug Administration (R01 FD003704, R01 FD006848)
- Cystic Fibrosis Foundation
This publication has 19 references indexed in Scilit:
- Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosisPediatric Pulmonology, 2012
- Failure to Recover to Baseline Pulmonary Function after Cystic Fibrosis Pulmonary ExacerbationAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Cystic Fibrosis Pulmonary GuidelinesAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Risk Factors For Rate of Decline in Forced Expiratory Volume in One Second in Children and Adolescents with Cystic FibrosisThe Journal of Pediatrics, 2007
- Exacerbations in cystic fibrosis {middle dot} 1: Epidemiology and pathogenesisThorax, 2007
- Estimating equations for association structuresStatistics in Medicine, 2004
- Developing Cystic Fibrosis Lung Transplant Referral Criteria Using Predictors of 2-Year MortalityAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Spirometric Reference Values from a Sample of the General U.S. PopulationAmerican Journal of Respiratory and Critical Care Medicine, 1999
- Pulmonary function between 6 and 18 years of agePediatric Pulmonology, 1993
- Quality of Well-Being Before and After Antibiotic Treatment of Pulmonary Exacerbation in Patients with Cystic FibrosisSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1990